Last reviewed · How we verify
Respiratory distress syndrome in the newborn
Approved treatments
- L-Dipalmitoyl Lecithin · GSK
- Infasurf · ONY
- Survanta · AbbVie
- Surfaxin · Discovery Labs
- Curosurf · Jean Michel Hascoet
- Cetanol · GSK
- Alevaire · GSK
- Curosurf · Chiesi Usa Inc
Curosurf works by reducing the surface tension in the lungs, allowing for easier breathing and improving oxygenation. - Survanta · NICHD Neonatal Research Network
- Infasurf · Children's Hospital of Philadelphia
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Respiratory distress syndrome in the newborn patent landscape — cliff calendar, originator estates, attackable patents
- Respiratory distress syndrome in the newborn treatment landscape brief
- Respiratory distress syndrome in the newborn treatment updates RSS
Frequently asked questions about Respiratory distress syndrome in the newborn
What drugs treat Respiratory distress syndrome in the newborn?
Tracked treatments include L-Dipalmitoyl Lecithin, Infasurf, Survanta, Surfaxin, Curosurf, Cetanol, Alevaire.
What is the treatment for Respiratory distress syndrome in the newborn?
Standard treatment for Respiratory distress syndrome in the newborn includes L-Dipalmitoyl Lecithin, Infasurf, Survanta, Surfaxin, Curosurf. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Respiratory distress syndrome in the newborn patent cliff · Respiratory distress syndrome in the newborn CI report
- Treatment: L-Dipalmitoyl Lecithin · GSK
- Treatment: Infasurf · ONY
- Treatment: Survanta · AbbVie
- Treatment: Surfaxin · Discovery Labs
- Treatment: Curosurf · Jean Michel Hascoet
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing